Weekly oral azithromycin as prophylaxis for agents causing acute respiratory disease.
about
Respiratory diseases among U.S. military personnel: countering emerging threats.Respiratory Infections in the U.S. Military: Recent Experience and ControlMycoplasma pneumoniae and its role as a human pathogen.Applying network theory to epidemics: control measures for Mycoplasma pneumoniae outbreaks.Once weekly azithromycin in secondary prevention of rheumatic feverAdverse and beneficial secondary effects of mass treatment with azithromycin to eliminate blindness due to trachoma in Nepal.Randomized, placebo-controlled clinical trial of oral azithromycin prophylaxis against respiratory infections in a high-risk, young adult population.Antibiotic Resistance in Young Children in Kilosa District, Tanzania 4 Years after Mass Distribution of Azithromycin for Trachoma Control.The HPLC assay of concentration of azithromycin from two different manufacturers in gingival crevicular fluid (GCF).Development of a genomics-based PCR assay for detection of Mycoplasma pneumoniae in a large outbreak in New York State.Anti-inflammatory activity of azithromycin as measured by its NF-kappaB, inhibitory activity.Presence of macrolide resistance in respiratory flora of HIV-Infected patients receiving either clarithromycin or azithromycin for Mycobacterium avium complex prophylaxis.Azithromycin prophylaxis during a hospitalwide outbreak of a pertussis-like illness.Two regimens of azithromycin prophylaxis against community-acquired respiratory and skin/soft-tissue infections among military trainees.Prevention of Invasive Group A Streptococcal Disease among Household Contacts of Case Patients and among Postpartum and Postsurgical Patients: Recommendations from the Centers for Disease Control and Prevention
P2860
Q33643096-0855EE91-268E-4C6A-8C2F-4E3381A7BA41Q35763405-9A841961-D414-43A8-87A6-60B29CB02EF8Q35920629-790E36E3-C3EB-4185-85F7-D7929CA48D1CQ36014980-72667EA8-E5E9-42B5-9F86-47111EA3F90BQ37387256-E3DB59E9-B85B-4945-8360-5388E0ADBF99Q37871521-6F2A9765-07A9-4F03-8921-ECF9FC22AFD0Q37873550-30CF05FE-AFA2-4932-A351-BE0162DF70FEQ38655295-CAA7C4FE-B0FB-4DB1-92AA-F83131DC13BAQ39079750-E75F95BA-D2DA-43A9-A1ED-D19F44BC76BCQ39464101-CE90FF3A-458C-4A70-AAE7-36D011F951D1Q39744364-1279F26A-1F12-4B41-B637-0B352A6053BDQ43822041-D62B41AF-A607-48BF-8A4C-6220B4A89539Q43904045-1F42FDC7-ADF4-4ED6-A66A-CBA854A993F4Q44850122-C8B8516B-B700-43E9-9E5B-23C34FEB8A90Q57661150-81E49305-9CAA-48CF-B56E-F0B82A3D2AF3
P2860
Weekly oral azithromycin as prophylaxis for agents causing acute respiratory disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 1998
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Weekly oral azithromycin as prophylaxis for agents causing acute respiratory disease.
@en
Weekly oral azithromycin as prophylaxis for agents causing acute respiratory disease.
@nl
type
label
Weekly oral azithromycin as prophylaxis for agents causing acute respiratory disease.
@en
Weekly oral azithromycin as prophylaxis for agents causing acute respiratory disease.
@nl
prefLabel
Weekly oral azithromycin as prophylaxis for agents causing acute respiratory disease.
@en
Weekly oral azithromycin as prophylaxis for agents causing acute respiratory disease.
@nl
P2093
P356
P1476
Weekly oral azithromycin as prophylaxis for agents causing acute respiratory disease.
@en
P2093
Cassell GH
Deperalta EP
Karcher JA
Leinonen M
McPhate DC
P304
P356
10.1086/516275
P407
P577
1998-01-01T00:00:00Z